Ophthalmic Composition For The Treatment Of Ocular Infection

Patent metadata

Field	Value
Publication number	US-2017196805-A1
Application number	US-201515314137-A
Country	US
Kind code	A1
Filing date	Jun 18, 2015
Priority date	Jun 20, 2014
Publication date	Jul 13, 2017
Grant date	—

Abstract

An ophthalmic composition for administration to an eye of a patient for the treatment of an ocular infection. The ophthalmic composition contains an ε-polylysine (εPL) in an amount effective to treat or control or prevent the ocular infection.

First claim

1 . An ophthalmic composition for use in the treatment of an ocular infection when the ophthalmic composition is administered to an eye of a patient, or the prophylaxis of an ocular infection when the ophthalmic composition is administered to an eye of a patient before or after the introduction of an inoculum of an ocular pathogen, said composition comprising an amount of ε-polylysine (εPL) effective for said treatment.

2 . The composition for use of claim 1 , wherein the ocular infection is bacterial conjunctivitis.

3 . The composition for use of claim 1 , wherein the ocular infection is bacterial keratitis.

4 . (canceled)

5 . The composition for use of claim 1 , wherein the ocular infection is bacterial endophthalmitis.

6 . The composition for use of claim 1 , wherein the ocular infection is caused by a methicillin-resistant Staphylococus aureus (MRSA).

7 . The composition for use of any preceding claim 1 , wherein the amount of εPL is between 0.001 and 2.0 percent by weight.

8 . The composition for use of claim 1 further comprising a viscosity-increasing agent.

9 . The composition for use of claim 1 further comprising a mucoadhesive agent.

10 . The composition for use of claim 1 further comprising an excipient that is a polyvinyl alcohol, polypropylene glycol, a carbomer, polycarbophil, a polyoxyethlene-polyoxypropylene block copolymer, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, carboxymethyl cellulose, hydroxyethyl cellulose, hyaluronic acid, dextran, chondroitin sulfate, gellan gum, xanthan gum, guar gum, trehalose, tamarind seed polysaccharide, or a cyclodextrin, or any combinations of any two or more of the foregoing excipients.

11 . The composition for use of claim 1 , wherein the composition comprises no preservative agent in addition to the ε-polylysine (εPL).

12 . The composition for use of claim 1 , wherein the composition is formulated as a liquid for administering by one or more drops to the eye.

13 . The composition for use of claim 1 , wherein the composition is formulated as a unit dose ocular insert for placement in the eye's cul de sac.

14 . An eye drop dispensing bottle comprising in liquid form, the ophthalmic composition for use in the treatment of prophylaxis of an ocular infection of claim 1 .

15 . A method for the treatment of an ocular infection of a patient, said method comprising topically administering of an ophthalmic composition comprising an effective amount of ε-polylysine (εPL) to the patient's eye, or a method for the prophylaxis of an ocular infection of a patient, said method comprising topically administering of an ophthalmic composition comprising an effective amount of ε-polylysine (εPL) to the patient's eye before or after the introduction of an inoculum of an ocular pathogen.

16 . The method of claim 15 , wherein the patient is a human or a veterinary patient.

17 . The method of claim 15 , wherein the method is for the treatment of bacterial conjunctivitis.

18 . The method of claim 15 , wherein the method is for the treatment of bacterial keratitis.

19 . The method of claim 15 , wherein the ocular infection is caused by MRSA.

20 . The method of claim 15 , wherein the ophthalmic composition is administered to the patient prior to cataract surgery for prophylaxis against bacterial endophthalmitis.

21 . Use of an ophthalmic composition comprising a pharmaceutically acceptable carrier and an effective amount of ε-polylysine (εPL) for the preparation of a medicament for topical administration to an eye of a patient for the treatment of an ocular infection or for the prophylaxis of an ocular infection when the ophthalmic composition is administered to an eye of a patient before or after the introduction of an inoculum of an ocular pathogen.

22 . The use of claim 21 , wherein the ocular infection is caused by MRSA.

Assignees

• Coopervision Int Holding Co Lp

Inventors

• Si Erwin C

Classifications

• A61K38/16 Primary

  Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof {(enzyme inhibitors A61K38/005)} · CPC title

• A61P31/04

  Antibacterial agents · CPC title

• A61K9/0048 Primary

  Eye, e.g. artificial tears · CPC title

• A61P27/02

  Ophthalmic agents · CPC title

• A61K9/0051

  Ocular inserts or implants · CPC title